By Admin 
The American pharmaceutical company Merck has signed a major agreement with China’s Jiangsu Hengrui Pharmaceuticals on Tuesday. Under this deal, Merc has got global rights on a new heart disease drug HRS-5346. The total value of this deal is $ 2 billion, about Rs 16,700 crore.
What is this new medicine?
HRS-5346 is an oral ie drug that is lipoprotein (A) [Lp(a)] Reduces a protein called. Let me tell you, LP (A) increases the risk of heart diseases and stroke at high level. 1 out of every 5 people worldwide are affected by this. This drug is currently passing through the Phase 2 clinical trial in China.
The main points of the deal
Merc has got an exclusive rights to develop, manufacture and sell this drug in the world (except for China, Hong Kong, Macao and Taiwan). Hengrui Pharma will get an advance amount of 200 million (about Rs 1,670 crore). If the drug is approved, Heng cotton can get additional payment of up to 1.77 billion (about Rs 14,800 crore). Apart from this, royalty will also be found on the cell of the medicine.
What do experts say?
Dr. Dean Y. Lee, President of Merck Research Labs, says on this report, “LP (A) is a big risk factor of heart diseases. This drug will strengthen our cardio-metabolic pipeline.” At the same time, Dr. Frank Jiang of Hengrui Pharma says, “This partnership with Merc will accelerate the development of HRS-5346 and give patients a new option.”
What will happen next?
This deal is dependent on the Hart-Scott-Rodino Act and other conditions. The deal is expected to be completed by the second quarter of 2025. Merc said that due to this deal, he will have to show a pre-tax charge of $ 200 million, which will affect his earnings.
Let me tell you, cases of cardiovascular disease are increasing rapidly worldwide. LP (A) The market for targeted drugs is large and Merc wants to take advantage of it. China’s pharma companies are now coming forward in global research.
Also read: 8th Pay Commission: From Justice Department to PSU … Not a single rupee will increase in 8th Pay Commission